Menarini group and radius health, inc. announce publication of elacestrant pivotal phase 3 emerald clinical trial data in the journal of clinical oncology

Florence, italy and boston, may 19, 2022 (globe newswire) -- the menarini group (“menarini”) and radius health, inc. (“radius”) (nasdaq: rdus) (collectively, the “companies”) today announced that data from the pivotal phase 3 emerald clinical trial (nct03778931) evaluating elacestrant as a monotherapy vs. standard of care (soc; fulvestrant or aromatase inhibitor, ai) for the treatment of er+/her2- advanced or metastatic breast cancer were published in the journal of clinical oncology 1. elacestrant is the first oral selective estrogen receptor degrader (serd) demonstrating a significant improvement in pfs vs. soc with manageable safety in a phase 3 trial for patients with er-positive/her2-negative advanced breast cancer.
RDUS Ratings Summary
RDUS Quant Ranking